Churchville, PA, United States of America

Tianbao Lu

This inventor holds 64 USPTO granted patents and 5 published patent applications, plus 3 CIPO patents and 13 EPO patents, primarily in Pharmaceutical Compounds (CPC class C07D). Top assignees: 3-Dimensional Pharmaceuticals, Inc., Janssen Pharmaceutica Nv, Ortho-Mcneil Pharmaceutical Corp.. Active years: 1997-2025.

USPTO Granted Patents = 64 (Patent Applications = 5)

% Patents Active = 79.7

CIPO Patents = 3 (Patent Applications = 4)

EPO Patents = 13 (Patent Applications = 10)

Average Co-Inventor Count = 4.9

ph-index = 9

Forward Citations = 330(Granted Patents)

Forward Citations (Not Self Cited) = 292(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Collegevile, PA (US) (2002)
Exton, PA (US) (1997 - 2004)
Kennet Square, PA (US) (2004)
Kennett Square, PA (US) (2002 - 2006)
Collegeville, PA (US) (2000 - 2008)
Churchville, PA (US) (2006 - 2024)

Company Filing History:

30 out of 77

3-Dimensional Pharmaceuticals, Inc.

patents

26 out of 2,099

Janssen Pharmaceutica Nv

patents

4 out of 363

Ortho-Mcneil Pharmaceutical Corp.

patents

4. 1 out of 2

Dimensional Pharmaceuticals, Inc.

patents

5. 1 out of 432

Janssen Biotech, Inc.

patents

6. 1 out of 1

Johnson & Johnson Pharmaceuticals Research & Development, L.l.c.

patent

7. 1 out of 834,350

Other

patents

Years Active: 1997-2025

Loading Chart...

Areas of Expertise:

MALT1 Inhibitors

FASN Inhibitors

Glucagon Receptor Antagonists

Protease Inhibitors

Thrombin Modulators

Kinase Modulators

Pyridine Derivatives

Indazole Derivatives

Pyrazole Derivatives

Aminoguanidines

Cyclic Compounds

Acylhydrazones

64 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12404260 - Pyridine rings containing derivatives as MALT1 inhibitors (2025-09-02),

2. 12077521 - Pyrazole derivatives as MALT1 inhibitors (2024-09-03),

3. 11897880 - 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors (2024-02-13),

4. 11814364 - Pyridine N-oxide derivatives useful as factor XIa inhibitors (2023-11-14),

5. 11472830 - Cyclic dinucleotides as sting agonists (2022-10-18),

6. 11098016 - Indazole derivatives useful as glucagon receptor antagonists (2021-08-24),

7. 11040031 - Pyrazole derivatives as MALT1 inhibitors (2021-06-22),

8. 10954214 - Pyrazole derivatives as MALT1 inhibitors (2021-03-23),

9. 10888550 - Pyrazole derivatives as MALT1 inhibitors (2021-01-12),

10. 10774048 - Indazole derivatives useful as glucagon receptor antagonists (2020-09-15),

11. 10413545 - Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer (2019-09-17),

12. 10214493 - Indazole derivatives useful as glucagon receptor antagonists (2019-02-26),

13. 10077261 - Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer (2018-09-18),

14. 10000473 - Indazole derivatives useful as glucagon receptor antagonists (2018-06-19),

15. 9718813 - Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer (2017-08-01),

Title: **The Innovative Journey of Tianbao Lu**

Introduction

Tianbao Lu, based in Churchville, PA, is a prolific inventor holding an impressive portfolio of 63 patents. His contributions to the field of pharmaceuticals showcase a commitment to advancing medical science through innovative compounds and therapeutic methods.

Latest Patents

Among his latest inventions, Lu has developed pyrazole derivatives that serve as MALT1 inhibitors. These compounds provide a potential pathway for treating various diseases and disorders influenced by MALT1 modulation. The disclosed compounds are represented by a specific formula, highlighting their complex chemical structure.

Additionally, Lu has presented 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives, which are designed as factor XIa inhibitors. This invention targets thromboembolic disorders and inflammatory conditions, where plasma kallikrein activity plays a significant role. These compounds, alongside their stereoisomers and pharmaceutical compositions, offer new avenues for the treatment and prophylaxis of serious health issues.

Career Highlights

Lu has made significant strides in his career, working with reputable companies such as 3-Dimensional Pharmaceuticals, Inc. and Janssen Pharmaceutica. His work has not only displayed innovation but also a dedication to developing effective therapeutic solutions that contribute to human health.

Collaborations

Throughout his career, Tianbao Lu has collaborated with esteemed colleagues, including Bruce Edward Tomczuk and Thomas P. Markotan. These collaborations have likely enriched his research and fostered the development of novel inventions that may significantly impact the pharmaceutical industry.

Conclusion

Tianbao Lu's journey exemplifies the intersection of science and innovation, with a strong portfolio of patents that reflect his dedication and expertise. His work in creating new therapeutic compounds not only showcases his inventive spirit but also holds promise for addressing critical health challenges in today's society.